Laughing Water Capital on X
Friendly reminder that $MRK is well positioned and well incentivized to purchase $LQDA. Yutrepia fits very well with Merck's respiratory portfolio. https://t.co/JAdLguTw7D
NYSE
Merck & Co., Inc.
MRK
2 articles
$376B Market cap · 2026-08-21
Laughing Water Capital on X
GSK faces a July 14 trial over Jemperli, with AnaptysBio claiming rights that could restrict PD-1 partnerships. The dispute could end in a settlement or acquisition.
